gap junction protein alpha 3Genealiases: CTRCT14 · CX46 · CZP3
Q-omics provides the consensus-scored GJA3 profile across patient tissues and cancer cell-line models. GJA3 expression is associated with patient survival in 23 of 34 cancer types, with the highest sampling consensus in UVM. Among the 18 cancer types available for tumor–normal comparison, GJA3 is differentially expressed in 13, with the highest sampling consensus in KIRP. Additionally, GJA3 RNA expression shows 15,230 significant gene co-expression associations, with the highest sampling consensus in UVM. Together, these results highlight UVM, and KIRP as cancer lineages where GJA3 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for GJA3 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes GJA3 survival associations across molecular data types. GJA3 RNA expression shows survival associations in the most cancer types (23), followed by mutation status (5) and mass-spec protein abundance (1). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible GJA3 RNA expression–survival associations across cancer types. High GJA3 expression shows unfavorable associations in UVM, MESO, BLCA, ACC, LGG and DLBC. The UVM Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify UVM as the clearest survival context for GJA3 RNA expression.
This table summarizes GJA3 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 13, while mass-spec protein shows differences in 1. The strongest signals are observed in KIRC for RNA and LSCC for protein.
This table ranks reproducible tumor–normal expression differences for GJA3. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. GJA3 shows lower tumor expression in KIRP and KIRC and higher tumor expression in COAD, LUSC, HNSC and BRCA. The KIRP box plot shows higher GJA3 RNA expression in normal versus tumor tissue (log2 FC = −1.524, t-test p < 0.001).
This table shows molecular features associated with GJA3 in patient tissues and cancer cell lines. In patient samples, GJA3 shows the broadest associations at the RNA and protein expression levels, with UVM recurring as the lineage with the largest associated feature set. In cancer cell lines, GJA3 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LUNG_SCLC, while CRISPR and shRNA rows add functional-dependency signals in SKIN and BLOOD_Myeloma.
